Ilsung Pharm - Asset Resilience Ratio
Ilsung Pharm (003120) has an Asset Resilience Ratio of 26.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Ilsung Pharm to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Ilsung Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Ilsung Pharm.
Liquid Assets Composition Over Time
This chart breaks down Ilsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Ilsung Pharm's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩105.96 Billion | 26.3% |
| Total Liquid Assets | ₩105.96 Billion | 26.30% |
Asset Resilience Insights
- Very High Liquidity: Ilsung Pharm maintains exceptional liquid asset reserves at 26.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ilsung Pharm Industry Peers by Asset Resilience Ratio
Compare Ilsung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Ilsung Pharm (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Ilsung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.21% | ₩105.65 Billion ≈ $71.60 Million |
₩403.01 Billion ≈ $273.11 Million |
-2.02pp |
| 2024-12-31 | 28.23% | ₩112.05 Billion ≈ $75.93 Million |
₩396.88 Billion ≈ $268.96 Million |
+10.26pp |
| 2023-12-31 | 17.97% | ₩75.33 Billion ≈ $51.05 Million |
₩419.19 Billion ≈ $284.08 Million |
+12.51pp |
| 2022-12-31 | 5.46% | ₩27.01 Billion ≈ $18.30 Million |
₩494.42 Billion ≈ $335.06 Million |
+1.90pp |
| 2021-12-31 | 3.57% | ₩13.24 Billion ≈ $8.97 Million |
₩371.38 Billion ≈ $251.68 Million |
+1.13pp |
| 2020-12-31 | 2.43% | ₩9.03 Billion ≈ $6.12 Million |
₩371.22 Billion ≈ $251.57 Million |
-1.54pp |
| 2019-12-31 | 3.98% | ₩14.69 Billion ≈ $9.95 Million |
₩369.52 Billion ≈ $250.42 Million |
-11.15pp |
| 2018-12-31 | 15.13% | ₩52.52 Billion ≈ $35.59 Million |
₩347.26 Billion ≈ $235.34 Million |
+11.89pp |
| 2017-12-31 | 3.24% | ₩11.25 Billion ≈ $7.62 Million |
₩347.46 Billion ≈ $235.47 Million |
-0.87pp |
| 2016-12-31 | 4.10% | ₩13.89 Billion ≈ $9.41 Million |
₩338.50 Billion ≈ $229.40 Million |
-13.18pp |
| 2015-12-31 | 17.28% | ₩63.43 Billion ≈ $42.99 Million |
₩367.03 Billion ≈ $248.73 Million |
-7.46pp |
| 2014-12-31 | 24.74% | ₩93.61 Billion ≈ $63.44 Million |
₩378.37 Billion ≈ $256.42 Million |
+1.20pp |
| 2013-12-31 | 23.54% | ₩87.73 Billion ≈ $59.45 Million |
₩372.66 Billion ≈ $252.55 Million |
-- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more